# Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

> **NCT04098744** · PHASE2 · RECRUITING · sponsor: **Frantz Viral Therapeutics, LLC** · enrollment: 78 (estimated)

## Conditions studied

- CIN 2/3
- HPV Infection
- Pre-Cancerous Dysplasia
- Cervical Dysplasia
- HPV Related Disease

## Interventions

- **DRUG:** Artesunate vaginal insert
- **DRUG:** Placebo vaginal insert

## Key facts

- **NCT ID:** NCT04098744
- **Lead sponsor:** Frantz Viral Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-09
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04098744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04098744, "Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04098744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*